Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
We assessed the frequency and severity of adverse events (AEs) in 53 patients with Chagas disease treated with nifurtimox in a US clinic. There were 435 AEs, but 93.8% were mild. Moderate/severe AEs were associated with premature treatment cessation.
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Oxford University Press
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036918/ |